MS is an autoimmune disease leading to a chronic inflammation of the central nervous system. Until now, the underlying cause of the disease has not been fully elucidated, but it can be modulated to limit disease progression and severity.
There is a clear need to identify biomarkers to support the development of superior therapeutics that can offer one or more of the following differentiating factors:
- Improved efficacy and/or safety profile;
- A novel mechanism of action;
- A preferable route of administration over currently available therapies.
To read the full proposal see http://www.bmglabtech.com/promotion/identification-of-biomarkers.cfm